Study of Inhaled TOBI for the Treatment of Early Infections of Pseudomonas Aeruginosa in children with CF ages 3 Months to less than 7 Years
Number of Participants Being Recruited:
Single / Multi-Center:
STUDY BACKGROUND INFORMATION:
This study will look at the effectiveness of inhaled TOBI treatment for early infections of P. aeruginosa in children with cystic fibrosis ages 3 months to less than 7 years.
3 Months - 7 Years
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Eligible subjects must have early lower respiratory tract infection with Pa defined by either of the following: The first time Pa is isolated, or Pa isolated after 1 year of negative cultures (documented with at least 2 negative cultures)
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
The sites listed below are currently recruiting subjects. Please note that this list generally lists either the pediatric or adult program but not both even though both programs may be recruiting subjects. Also, this list does not include sites that may be participating in the study but are not yet open for recruitment. If you are interested in this study please contact your center for more information.
Miller Children's Hospital (Pediatric), Long Beach, CA, 90801
O'Donnell, Nan Phone: (562) 933-5607 Email: email@example.com